Posts

Posted on

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.

Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients in the placebo-controlled pivotal back pain trial ensures the trial is well powered for success. Commercial manufacturing is proceeding in parallel so that we can file for approval as soon as possible after trial results readout.”

CLBP caused by inflammation and degenerative disc disease is a serious condition with a prevalence of over 7 million people in the U.S. alone. The indication is a potential blockbuster for Mesoblast with potential peak year revenue of >US$10 billion with single digit market penetration.

The trial’s primary endpoint is powered to show a significant difference in reduction of low back pain at 12 months between rexlemestrocel-L and sham controls. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids.

Rexlemestrocel-L has Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for treatment of CLBP due to degenerative disc disease providing eligibility for priority review once the Biologics License Application (BLA) has been filed. Top-line results are expected in mid-CY2027 after the last treated patient has completed 12 months follow-up.

About Rexlemestrocel-L for Chronic Low Back Pain associated with Degenerative Disc Disease

The 300-patient randomized controlled confirmatory Phase 3 trial of Mesoblast’s second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell product candidate rexlemestrocel-L in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc is actively enrolling in patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease (DDD) of less than five years duration at multiple sites across the U.S.

FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication. This endpoint was successfully met in Mesoblast’s first Phase 3 trial. Key secondary measures include improvement in quality of life and function.

A particular focus is on treatment of patients on opioids, since discogenic back pain accounts for approximately 50% of prescription opioid usage in the U.S. Significant pain reduction and opioid cessation were observed in Mesoblast’s first Phase 3 trial.

FDA has designated rexlemestrocel-L a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of chronic low back pain. RMAT designation provides all the benefits of Breakthrough and Fast Track designations, including rolling review and eligibility for priority review on filing of a Biologics License Application (BLA).

About Chronic Low Back Pain

Back pain is the leading cause of disability in Americans under 45 years,1 with an annual prevalence in the general U.S. adult population of 10-30%.2 CLBP caused by inflammation and degenerative disc disease (DDD) is a serious condition with a prevalence of over 7 million people in the U.S. alone.3,4 CLBP due to DDD is a leading cause of disability, and is associated with impaired quality of life, severe limitations in ability to perform activities of daily living, reduced ability to work, and negative impacts on mental health. CLBP accounts for approximately 50% of prescription opioid usage in the U.S., making the condition a significant contributor to the opioid epidemic.

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

  1. American Academy of Pain Medicine – Get the Facts on Pain. The American Academy of Pain Medicine. http://www.painmed.org/patientcenter/facts-on-pain/ Accessed on June 28, 2017.
  2. Urits I, Burshtein A, Sharma M, et al. Low Back Pain, a Comprehensive Review: Pathophysiology, Diagnosis, and Treatment. Current Pain and Headache Reports. 2019;23(3):1-10. doi:10.1007/s11916-019-0757-1.
  3. Navigant: Commercial Assessment for a Proprietary Cell-Based Therapy for DDD in the U.S. and the EU3 – August 2014.
  4. Decision Resources: Chronic Pain December 2015.

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:


Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
 

Media – Global

Media – Australia
Rubenstein BlueDot Media
Caroline Nelson Steve Dabkowski
T: +1 703 489 3037 T: +61 419 880 486
E: [email protected] E: [email protected]



Posted on

Grant & Eisenhofer Files Class Action Lawsuit Against Roblox Corporation, Extending Class Period of Previously Filed Action

Grant & Eisenhofer Files Class Action Lawsuit Against Roblox Corporation, Extending Class Period of Previously Filed Action

NEW YORK–(BUSINESS WIRE)–
Today, Grant & Eisenhofer P.A. filed a class action lawsuit on behalf of the Police and Fire Retirement System of the City of Detroit against Roblox Corporation (“Roblox” or the “Company”), Roblox’s CEO David Baszucki, Roblox’s CFO Naveen Chopra, and Roblox’s former CFO Michael Guthrie (collectively, the “Defendants”). The action alleges that Defendants defrauded investors by making materially false and/or misleading statements and failing to disclose material adverse facts regarding the lack of adequate safety infrastructure on Roblox’s platform and, later, that the implementation of enhanced age verification technology in response to governmental pressure would materially impair the Company’s financial results and growth.

The action, brought in the United States District Court for the Northern District of California, is captioned Police and Fire Retirement System of the City of Detroit v. Roblox Corp. et al., No. 3:26-cv-07160 (N.D. Cal.). It is related to the action captioned Mukherjee v. Roblox Corporation et al., No. 4:26-cv-05489 (N.D. Cal.). The action expands the class period asserted in the Mukherjee action so that it now includes all persons or entities who purchased or acquired Roblox common stock from October 31, 2024, through April 30, 2026, inclusive (the “Class Period”).

Roblox is an online gaming and gaming development platform which allows users to play, create, and monetize millions of user-generated 3D games or “experiences,” boasting well over 100 million daily active users. The Roblox platform also contains a social component, which lets its users interact through a chat function. Roblox is popular with children, with a majority of its daily active users under the age of sixteen and 40% under the age of twelve.

The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the lawsuit alleges that throughout the Class Period, Defendants issued a series of materially false and misleading statements which led investors to believe that its platform was safe for children. Later, after a flurry of litigation by ten state attorneys general alleging that Roblox’s platform lacked sufficient safeguards for children, Defendants announced the Company would be rolling out new age verification technology globally beginning in January 2026. Defendants downplayed the effect of these safety enhancements and claimed that the new technology would not have any meaningful effect on the growth trajectory of the Company.

Investors slowly learned the truth through a series of disclosures beginning on October 30, 2025. That day, the Company revealed that it would be instituting enhanced age verification technology globally beginning in January 2026. On this news, the price of the Company’s common stock declined 16% from $133.74 per share to $113.00 per share, wiping out $13 billion in market value.

Then on April 30, 2026—just three months after Roblox assured investors that the global rollout of the Company’s new age verification software would not impact the Company’s growth—Roblox disclosed it would be dramatically slashing its bookings guidance by $1 billion due to the new age verification software, which would significantly reduce its daily active users for the foreseeable future. On this news the price of the Company’s common stock declined from a market price of $55.26 per share at the close of trading on April 30, 2026, to $45.13 per share on May 1, 2026, a decline of 18.33%.

Investors who purchased or acquired Roblox common stock during the Class Period are members of this proposed Class and may be able to seek appointment as lead plaintiff, which is a court-appointed representative of the Class, by complying with the relevant provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). See 15 U.S.C. Section 78u-4(a)(2)(A)(i)-(iv).

If you wish to serve as lead plaintiff, you must move the Court by no later than August 7, 2026. You do not need to seek to become a lead plaintiff in order to share in any possible recovery. You may also retain counsel of your choice to represent you in this action.

If you wish to discuss this action or have any questions concerning this notice or your rights, please contact Karin E. Fisch at Grant & Eisenhofer at 646-722-8500, or via email at [email protected]. You can also find more information at gelaw.com.

Karin Fisch

Grant & Eisenhofer P.A.

Tel.: (646) 722-8500

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Posted on

Photronics, Inc. (PLAB) Faces Securities Class Action Amid IC Reality That Wiped Out $1.1 Billion of Market Capitalization – HBSS

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Photronics, Inc. (NASDAQ: PLAB) faces a securities class action lawsuit after its investors saw the price of their shares plunge $19.49 (-36%) on May 28, 2026. The move lower was triggered by the company’s Q2 2026 results that brought into question the propriety of its earlier statements about its operations and prospects regarding its high-end integrated circuit (“IC”) photomask product line.

The lawsuit seeks to represent investors who purchased or otherwise acquired Photronics securities between December 10, 2025 and May 27, 2026.

National shareholders’ rights firm Hagens Berman is continuing its investigation into the legal claims that Photronics and its management misled investors and violated the federal securities laws. The firm encourages Photronics investors who suffered substantial losses to submit your losses now.

Class Period: Dec. 10, 2025 – May 27, 2026
Lead Plaintiff Deadline: Sept. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/plab
Contact the Firm Now: [email protected]
                                        844-916-0895

Photronics, Inc. (PLAB) Securities Class Action:

Photronics is a leading manufacturer of photomasks, high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. IC sales comprise the bulk of Photronics’ total revenues.

During the Class Period, Photronics and its management touted “record in high-end IC […] thanks to a strong technology portfolio and exceptional execution.” They also emphasized that the company’s “[h]igh-end IC strength reflects strong order patterns globally, including in the U.S., […] where reshoring efforts continue to create a favorable demand environment.”

The company and its management continued to emphasize the “strong demand” for its high-end IC business throughout the Class Period and assured investors that “high-end strength will continue, as order demand remains healthy, to partially mitigate the upcoming seasonal impact following the Chinese New Year.”

The complaint alleges that Photronics and its management created the false impression that they had reliable information about revenue projections and growth while minimizing risks presented by post-holiday seasonality and macroeconomic fluctuations. The complaint further alleges that Photronics did not disclose to investors that its high-end chip design release pipeline was experiencing severe and ongoing bottlenecks due to elevated foundry use rates and equipment cost pressures.

On May 28, 2026 investors learned the truth. That day, Photronics’ operational reality became apparent when the company reported dismal financial results for its Q2 2026. Among the areas of concern were sequential declines in revenues (-6.7%), IC revenues (-11%), operating margins (-17.6%), GAAP net income (-26.8%), and non-GAAP net income (-30%).

In contrast to Class Period assurances, Photronics management in large part pinned the blame for the company’s consolidated and IC revenue declines on seasonality — “the seasonal recovery following the Chinese New Year has not occurred[.]” The company also revealed that bottlenecks had been created by high fab usage rates and a surge in memory prices.

In response, the market sent the price of Photronics shares down 36%, wiping out over $1.1 billion of the company’s market capitalization in a single day.

“Our investigation is focused on when Photronics and its management first knew that the company’s outlook and demand for its IC was deteriorating such that sequential and year-over-year revenues were declining,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Photronics and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Photronics case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Photronics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895



Posted on

Hub Group (HUBG) Securities Class Action Follows Admitted Years-Long Improper Accounting, Executive Ousters, Investor Losses – HBSS

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Hub Group, Inc. (NASDAQ: HUBG) and certain of its current and former executives (together, “co-defendants”) face a securities class action lawsuit, which seeks to represent investors who purchased or acquired Hub Group securities between April 28, 2023 and May 11, 2026.

The development follows the company’s surprise revelations that its financial reports going back to 2023 were “materially misstated and should no longer be relied upon” and corrective actions taken against two senior executives.

National shareholder rights firm Hagens Berman continues to investigate legal claims that Hub Group and its co-defendants violated the federal securities laws and urges investors who suffered significant losses to submit your losses now.

Class Period: Apr. 28, 2023 – May 11, 2026
Lead Plaintiff Deadline: Aug. 28, 2026
Visit:www.hbsslaw.com/investor-fraud/hubg
Contact the Firm Now:[email protected]
                                       844-916-0895

Hub Group, Inc. (HUBG) Securities Class Action:

The lawsuit focuses on the propriety of Hub Group’s repeated assurances that its financial statements were prepared in conformity with applicable accounting rules.

Contrary to these assurances, the complaint alleges that throughout the Class Period the co-defendants made false and misleading statements concerning Hub Group’s premature and incorrect revenue recognition and understatement of purchased transportation costs and accounts payable.

Investors learned the truth through a series of Hub Group’s partial disclosures about its accounting and ramifications for certain of its executives.

First, on February 6, 2026, investors saw the price of their Hub Group shares crater $9.37 (-18%) after the company (while touting that “[a]ccuracy and transparency in reporting on our performance is of utmost importance[]”) revealed that during the first nine months of 2025 it had understated purchased transportation costs and accounts receivable by $77 million. Accordingly, the company said investors should not rely on its Q1 – Q3 2025 financial statements and it plans to restate them.

Second, on May 12, Hub Group shares tumbled again – this time, shares fell $5.24 (-12.5%) – on new disclosures much worse than on February 6. The company said its financial statements for the years ended December 31, 2023 and 2024 were materially misstated and that investors should no longer rely on those either. Hub Group explained only that it “identified certain transactions that were prematurely or incorrectly recognized or not adequately supported[]” and cautioned it was continuing to review “additional accounting issues that may potentially further impact” the 2023 and 2024 financial statements.

Between February 5, 2026 (the day before Hub Group’s first partial corrective disclosure) and May 12, 2026, shareholders have seen over $890 million of Hub Group’s market capitalization wiped out.

After the Class Period, on June 2, 2026, Hub Group announced that Chief Financial Officer Kevin Beth and Chief Operating Officer Brian Meents both left the company on May 27. The company said the executive departures were part of its corrective actions related to its financial statement review.

“Now that Hub Group has almost cleaned out its C-suite following accounting improprieties reaching all the way back to 2023, the core focus of our investigation is whether they were intentional or reckless with the goal of making financial metrics appear better than they actually were. We’re also looking to see whether additional problems will surface when the company’s review is completed,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Hub Group and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Hub Group case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Hub Group should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895



Posted on

Peabody Energy Corporation (BTU) Faces Securities Class Action Related to Surprise Centurion Problems – HBSS

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Peabody Energy Corporation (NYSE: BTU) faces a securities class action lawsuit related to surprise disclosures the company made to investors on March 30 and May 5, 2026 about problems with its flagship metallurgical coal asset (“Centurion”).

The lawsuit seeks to represent investors who purchased or otherwise acquired shares of Peabody common stock between October 14, 2024 and May 4, 2026.

Between March 27 (the trading day before the first cryptic disclosure) and the May 5, 2026 fuller disclosure, investors saw the price of Peabody shares crumble $14.50 (-36%). Accordingly, the severe market reactions upon the company’s revelations support national shareholder rights firm Hagens Berman’s investigation into legal claims that Peabody and its co-defendants violated the federal securities laws.

The firm encourages Peabody investors who suffered substantial losses to submit your losses now.

Class Period: Oct. 14, 2024 – May 4, 2026
Lead Plaintiff Deadline: Aug. 24, 2026
Visit:www.hbsslaw.com/investor-fraud/btu
Contact the Firm Now: [email protected] | 844-916-0895

Peabody Energy Corporation (BTU) Securities Class Action:

Peabody characterizes itself as a leading producer of metallurgical and thermal coal and has promoted Centurion, its underground longwall metallurgical coal mine in Queensland, Australia. According to the company, the mine commenced full-scale production in February 2026.

The litigation is focused on the propriety of Peabody’s statements about Centurion’s operational status and production capabilities.

For example, Peabody’s management informed investors on February 5, 2026 that “the team was installing the very last shield and putting the finishing touches on the Centurion Mine[,]” and “our team is charged up and has started mining some of the best metallurgical coal in the world.” The company and its management also assured investors that Centurion is “going to ramp up probably about 700,000 tons in Q1, about 1 million to 1.1 million tons in Q2 and Q3, and then it’ll fall back down in Q4 as we have a longwall move.” In response, the market rewarded these statements by sending the price of Peabody shares up about 7.8% the next day.

Just a few weeks later, on March 30, 2026, Peabody filed a current report with the SEC and abruptly disclosed that Centurion “is expected deliver approximately 250,000 tons in the first quarter[.]” In other words, the company slashed Centurion production by about 64%. The news sent the price of Peabody shares down almost 10%.

Then, on May 5, 2026, Peabody reported its Q1 2026 financial results. Of particular concern pertaining to Centurion, management revealed the truth about why it slashed the mine’s Q1 production assurance.

Despite telling investors in February that it was mining Centurion and would produce 700,000 tons in Q1, a new narrative emerged – “as part of our commissioning in February, we encountered temporary mechanical and electrical issues” – and “[a]s a result, our full year sales outlook for Centurion is now 2.5 million tons compared to our original expectation of 3.5 million tons.” This full year 28% reduction helped send the price of Peabody shares down nearly 6%.

“We’re focused on whether Peabody and its management were sufficiently transparent about Centurion’s operational capabilities during the Class Period and, if not, whether they violated federal securities laws,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Peabody Energy and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Peabody case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Peabody Energy should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895



Posted on

Black Rock Coffee Bar, Inc. (BRCB) Faces Securities Class Action Related to IPO Disclosures Regarding Adverse Impact of Sales Transfer Phenomenon – HBSS

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (NASDAQ: BRCB) faces a securities class action lawsuit related to disclosures the company made to investors within its initial public offering documents whereby it issued about 16.9 million shares to investors at $20 per share. The lawsuit seeks to represent investors who purchased or otherwise acquired Black Rock common stock in and/or traceable to the company’s September 2025 IPO.

By the time the lawsuit was filed on June 18, 2026, Black Rock Coffee shares had steadily declined to $7.72, or over 61% below the IPO price.

The recent revelations about Black Rock Coffee’s slowing growth metrics and severe share price decline support national shareholder rights firm Hagens Berman’s investigation into legal claims that Black Rock and its co-defendants violated the federal securities laws.

The firm encourages Black Rock investors who suffered substantial losses to submit your losses now.

Lead Plaintiff Deadline: Aug. 17, 2026
Visit:www.hbsslaw.com/investor-fraud/brcb
Contact the Firm Now: [email protected] | 844-916-0895

Black Rock Coffee Bar, Inc. (BRCB) Securities Class Action:

Black Rock characterizes itself as a “high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by our engaging baristas.”

Within the company’s offering documents, it touted an aggressive growth story, stating that it has opened and plans to open additional stores in markets where it has little or no operating experience. To support its business plan, Black Rock cited metrics such as increasing store count, increasing store revenue, increasing same store sales (“SSS”) growth, increasing income from operations, and others.

The complaint alleges that Black Rock’s IPO documents misled investors because they did not disclose critical information to investors, such as new store openings were leading to a cannibalization of its existing services and revenue. In addition, the complaint alleges that Black Rock overstated the manner in which its expansion strategy was tailored to avoid situations where a portion of volume from existing stores shifts to newer stores in closer proximity to customers (“sales transfer”) that negatively affected revenue growth.

On May 12, 2026, Black Rock reported its Q1 2026 financial results. The company reported a large sequential decrease (-44%) in SSS growth – down from 9.3% to 5.2%. Of critical importance, during the earnings call that day, management revealed that the sales transfer phenomenon (i.e. cannibalization) created a 160-basis point headwind to SSS growth, raising doubts about the efficacy of Black Rock’s expansion strategy.

The company also reported opening nine new stores during the quarter, yet sequentially added just $1.9 million of revenues representing a slowing sequential growth rate to about 3.5%.

In response, the market drove the price of Black Rock shares down $3.32 (-30%) on May 13, 2026.

“We’re focused on whether Black Rock Coffee’s IPO documents were negligently prepared for failing to disclose adverse facts about the sales transfer phenomenon embedded in the company’s growth strategy,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Black Rock Coffee and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Black Rock Coffee case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Black Rock Coffee should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895



Posted on

Oak Valley Community Bank Announces Commercial Banking Officer Hiring

OAKDALE, Calif., July 13, 2026 (GLOBE NEWSWIRE) — Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), is pleased to announce that Joel Burns has joined the Bank as Vice President, Commercial Banking Officer. Based at the Bank’s Lodi Branch, located at 31 South School Street, Burns will serve commercial and agricultural clients throughout the Lodi market.

Burns brings 25 years of commercial banking experience, with extensive expertise in relationship management and business lending. Most recently, he served as a Commercial Banker at another local financial institution. In his new role, he will focus on commercial and agricultural lending, working closely with business owners to understand their goals and deliver customized financial solutions that support their long-term success.

“Joel brings a strong background in commercial banking, with a focus on building lasting client relationships and delivering thoughtful credit solutions for agricultural businesses,” said Gary Stephens, Executive Vice President, Commercial Banking Group. “His collaborative approach and commitment to understanding each client’s unique needs help foster the trusted partnerships that are at the heart of our relationship-based banking philosophy.”

Burns earned a Bachelor of Science in Agribusiness from California Polytechnic State University, San Luis Obispo, and is a graduate of the Southwestern Graduate School of Banking at Southern Methodist University. He is actively involved with the Lodi District Grape Growers Association. Outside of work, he enjoys spending time with family and friends.

Oak Valley Bancorp operates Oak Valley Community Bank & their Eastern Sierra Community Bank division, through which it offers a variety of loan and deposit products to individuals and small businesses. They currently operate through 19 conveniently located branches: Oakdale, Turlock, Stockton, Patterson, Ripon, Escalon, Manteca, Tracy, Sacramento, Roseville, Lodi, two branches in Sonora, three branches in Modesto, and three branches in the Eastern Sierra division which includes Bridgeport, Mammoth Lakes, and Bishop.

For more information, call 1-866-844-7500 or visit www.ovcb.com.

Contact: Rick McCarty
Phone: (209) 848-BANK (2265)
  Toll Free (866) 844–7500
  www.ovcb.com



Posted on

Jones Ventures INTL Acquisition1 Corp Announces Pricing of $200 Million Initial Public Offering

NEW YORK, NY, July 13, 2026 (GLOBE NEWSWIRE) — Jones Ventures INTL Acquisition1 Corp (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today that it has priced its initial public offering of 20,000,000 units at $10.00 per unit. Each unit consists of one Class A ordinary share and one right to receive one eighth (1/8) of a Class A ordinary share upon the consummation of an initial business combination. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, July 14, 2026, under the ticker symbol “JONEU.” Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on the Nasdaq under the symbols “JONE” and “JONER,” respectively.

JonesTrading Institutional Services LLC is acting as sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

The Company is led by Harsha Agadi, Chairman, Alan F. Hill, Chief Executive Officer and Bryan Turley, Chief Financial Officer.

The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from: JonesTrading Institutional Services LLC, 325 Hudson St, 6th Floor New York, NY 10013, or by e-mail at [email protected].

A registration statement relating to the securities was filed with, and declared effective by, the Securities and Exchange Commission (“SEC”) on July 13, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement filed with the SEC and the preliminary prospectus included therein. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

About Jones Ventures INTL Acquisition1 Corp

Jones Ventures INTL Acquisition1 Corp is a newly organized blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. 

Media Contact:

Bryan Turley
[email protected]



Posted on

HBSS Investigating Claims Against Roblox (RBLX) In Pending Securities Class Action Over Alleged Misleading Statements Regarding Age-Check Rollout Impact

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — National shareholder rights firm Hagens Berman is investigating claims alleged in a pending securities class action suit against Roblox Corporation (NYSE: RBLX) and its management following disclosures that the company’s age verification rollout caused significant, undisclosed friction to its user growth and platform engagement.


SUBMIT YOUR RBLX LOSSES TO HBSS NOW

The firm’s investigation focuses on the suit’s claims that Defendants misled investors regarding the operational consequences of the safety-focused initiatives the company had purportedly implemented.

Allegations Concerning Age Verification and Growth:

The suit follows a sharp decline in Roblox’s share price on May 1, 2026, after the company reported its Q1 2026 financial results. The core allegations, which have emerged in recently filed complaint against the company, contend that Roblox failed to disclose that its age-check rollout:

  • Reduced Platform Engagement: The age verification features hindered on-platform communication, leading to a decline in user interaction.
  • Negatively Impacted Organic Growth: The friction caused by these features resulted in lower app store ratings and a corresponding reduction in organic user sign-ups.
  • Misrepresented Growth Potential: Throughout the class period (October 30, 2025 – April 30, 2026), Roblox characterized the rollout as a “gold standard” implementation while allegedly knowing it would lead to a significant slowdown in user growth.

Key Disclosures and Market Impact

  • April 30, 2026: Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance and severely cut its 2026 bookings growth. The company blamed its dismal results on just 51% of Roblox global DAUs having age checked. The company further revealed that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.
  • Market Correction: The news caused Roblox shares to fall $10.13, or approximately 18.33%, on May 1, 2026, erasing over $6.7 billion in market capitalization.

Hagens Berman’s Investigation

“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors about it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Lead Plaintiff Deadline

Hagens Berman is currently evaluating the claims alleged in the suit brought on behalf of a putative class of investors who purchased Roblox securities between October 30, 2025, and April 30, 2026. If you suffered financial losses on RBLX during the class period, you are encouraged to contact our office to learn more about your legal rights and the ongoing class action litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 7, 2026.

If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895



Posted on

Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business — HBSS

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company’s disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts’ questions.

These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into claims that Embecta violated the federal securities laws.

The firm encourages Embecta investors who suffered substantial losses to submit your losses now.

Class Period: Nov. 25, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 17, 2026
Visit:www.hbsslaw.com/investor-fraud/embc
Contact the Firm Now: [email protected]
                                       844-916-0895

Embecta Corp. (EMBC) Securities Class Action:

Embecta is a global medical device company whose core business product is pen needles – sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. In the past, pen needle revenues have comprised over 70% of the company’s total revenues.

The litigation’s primary focus is on the propriety of Embecta’s Class Period repeated assurances that “insulin pens have been stable […] showing the underlying resilience and the durability of that portfolio[]” and “our pen needle business is incredibly resolute.” This narrative formed the basis for the company’s February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80 – $3.00.  The company also touted maintenance of its dividend within its capital allocation plans as a return of capital to shareholders.

The complaint alleges the company’s assurances and guidance were misleading when given because Embecta knew or recklessly disregarded that weaknesses in the pen needle market was likely to significantly disrupt the company’s annual guidance and Q2 results.

On May 5, 2026, investors’ expectations vanished. That day, Embecta reported Q2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year decline of about 61%. In contrast to the company’s assurances of stability, resilience, and durability, Embecta’s pen needles revenues also suffered massive sequential and year-over-year declines. Of additional concern, Embecta slashed its 2026 adjusted EPS guidance to $1.55 – $1.75, or down roughly 43% at the mid-point, and reduced its dividend by 93% to just $0.01.

In response, the market sent the price of Embecta shares tumbling, with one prominent analyst who downgraded the company highlighting Embecta management’s “need to rebuild investor credibility on commercial execution and the profitability outlook.”

“Our investigation is focused the extent to which and when Embecta and its management knew about pen needle and U.S. business revenue headwinds, and whether they were sufficiently transparent about those risks,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Embecta and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Embecta case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Embecta should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895